PEGylation as a strategy for improving nanoparticle-based drug and gene delivery

Abuchowski, 1977, Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase, J. Biol. Chem., 252, 3582, 10.1016/S0021-9258(17)40292-4

Weissig, 2014, Nanopharmaceuticals (part 1): products on the market, Int. J. Nanomedicine, 9, 4357, 10.2147/IJN.S46900

Arturson, 1983, Acrylic microspheres in vivo IX: blood elimination kinetics and organ distribution of microparticles with different surface characteristics, J. Pharm. Sci., 72, 1415, 10.1002/jps.2600721213

Tan, 1993, Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats, Biomaterials, 14, 823, 10.1016/0142-9612(93)90004-L

Klibanov, 1990, Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes, FEBS Lett., 268, 235, 10.1016/0014-5793(90)81016-H

Ahmed, 2005, Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time, J. Vasc. Interv. Radiol., 16, 1365, 10.1097/01.RVI.0000175324.63304.25

Gabizon, 2003, Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies, Clin. Pharmacokinet., 42, 419, 10.2165/00003088-200342050-00002

Laginha, 2005, Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors, Clin. Cancer Res., 11, 6944, 10.1158/1078-0432.CCR-05-0343

Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283

Braet, 2007, Contribution of high-resolution correlative imaging techniques in the study of the liver sieve in three-dimensions, Microsc. Res. Tech., 70, 230, 10.1002/jemt.20408

Alexis, 2008, Factors affecting the clearance and biodistribution of polymeric nanoparticles, Mol. Pharm., 5, 505, 10.1021/mp800051m

Vonarbourg, 2006, Parameters influencing the stealthiness of colloidal drug delivery systems, Biomaterials, 27, 4356, 10.1016/j.biomaterials.2006.03.039

Aderem, 1999, Mechanisms of phagocytosis in macrophages, Annu. Rev. Immunol., 17, 593, 10.1146/annurev.immunol.17.1.593

Patel, 1992, Serum opsonins and liposomes: their interaction and opsonophagocytosis, Crit. Rev. Ther. Drug Carrier Syst., 9, 39

Gessner, 2000, Nanoparticles with decreasing surface hydrophobicities: influence on plasma protein adsorption, Int. J. Pharm., 196, 245, 10.1016/S0378-5173(99)00432-9

Roser, 1998, Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats, Eur. J. Pharm. Biopharm., 46, 255, 10.1016/S0939-6411(98)00038-1

Yoon, 1998, Interpretation of protein adsorption phenomena onto functional microspheres, Colloids Surf. B, 12, 15, 10.1016/S0927-7765(98)00045-9

Arnida, 2011, Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages, Eur. J. Pharm. Biopharm., 77, 417, 10.1016/j.ejpb.2010.11.010

Liu, 1996, Serum independent liposome uptake by mouse liver, Bba-Biomembranes, 1278, 5, 10.1016/0005-2736(95)00196-4

Walkey, 2012, Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake, J. Am. Chem. Soc., 134, 2139, 10.1021/ja2084338

Monopoli, 2012, Biomolecular coronas provide the biological identity of nanosized materials, Nat. Nanotechnol., 7, 779, 10.1038/nnano.2012.207

Tenzer, 2013, Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology, Nat. Nanotechnol., 8, 772, 10.1038/nnano.2013.181

Salvati, 2013, Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface, Nat. Nanotechnol., 8, 137, 10.1038/nnano.2012.237

Li, 1998, Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery, Gene Ther., 5, 930, 10.1038/sj.gt.3300683

Bragonzi, 1999, Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs, Gene Ther., 6, 1995, 10.1038/sj.gt.3301039

Liu, 1997, Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery, Nat. Biotechnol., 15, 167, 10.1038/nbt0297-167

Yoo, 2010, Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects, Curr. Pharm. Des., 16, 2298, 10.2174/138161210791920496

Yang, 2015, Anti-PEG immunity: emergence, characteristics, and unaddressed questions, Wiley interdisciplinary reviews, Nanomed. Nanobiotechnol., 7, 655, 10.1002/wnan.1339

Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science, 263, 1600, 10.1126/science.8128245

Stirland, 2013, Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice, J. Control. Release, 172, 1045, 10.1016/j.jconrel.2013.09.026

Kim, 2012, Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials, Biomaterials, 33, 1838, 10.1016/j.biomaterials.2011.11.020

Lee, 2005, PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization, Biotechnol. Bioeng., 92, 24, 10.1002/bit.20562

Matsumura, 1986, A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res., 46, 6387

Hobbs, 1998, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci. U. S. A., 95, 4607, 10.1073/pnas.95.8.4607

Dawidczyk, 2014, State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines, J. Control. Release, 187, 133, 10.1016/j.jconrel.2014.05.036

von Maltzahn, 2009, Computationally guided photothermal tumor therapy using long-circulating gold nanorod antennas, Cancer Res., 69, 3892, 10.1158/0008-5472.CAN-08-4242

van der Meel, 2013, Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status, Adv. Drug Deliv. Rev., 65, 1284, 10.1016/j.addr.2013.08.012

Nance, 2014, Non-invasive delivery of stealth, brain-penetrating nanoparticles across the blood–brain barrier using MRI-guided focused ultrasound, J. Control. Release, 189, 123, 10.1016/j.jconrel.2014.06.031

Kennedy, 2004, High-intensity focused ultrasound for the treatment of liver tumours, Ultrasonics, 42, 931, 10.1016/j.ultras.2004.01.089

Gref, 2000, ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, Colloids Surf. B: Biointerfaces, 18, 301, 10.1016/S0927-7765(99)00156-3

Miteva, 2015, Tuning PEGylation of mixed micelles to overcome intracellular and systemic siRNA delivery barriers, Biomaterials, 38, 97, 10.1016/j.biomaterials.2014.10.036

Mori, 1991, Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo, FEBS Lett., 284, 263, 10.1016/0014-5793(91)80699-4

Gref, 1995, The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres, Adv. Drug Deliv. Rev., 16, 215, 10.1016/0169-409X(95)00026-4

Jokerst, 2011, Nanoparticle PEGylation for imaging and therapy, Nanomedicine (Lond), 6, 715, 10.2217/nnm.11.19

Dos Santos, 2007, Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding, Biochim. Biophys. Acta, 1768, 1367, 10.1016/j.bbamem.2006.12.013

Owens, 2006, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, Int. J. Pharm., 307, 93, 10.1016/j.ijpharm.2005.10.010

Cui, 2015, Engineering poly(ethylene glycol) particles for improved biodistribution, ACS Nano, 9, 1571, 10.1021/nn5061578

He, 2010, The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses, Biomaterials, 31, 1085, 10.1016/j.biomaterials.2009.10.046

Perrault, 2009, Mediating tumor targeting efficiency of nanoparticles through design, Nano Lett., 9, 1909, 10.1021/nl900031y

Mosqueira, 1999, Interactions between a macrophage cell line (J774A1) and surface-modified poly (D, L-lactide) nanocapsules bearing poly(ethylene glycol), J. Drug Target., 7, 65, 10.3109/10611869909085493

Mosqueira, 2001, Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density, Pharm. Res., 18, 1411, 10.1023/A:1012248721523

Bazile, 1995, Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system, J. Pharm. Sci., 84, 493, 10.1002/jps.2600840420

Fang, 2006, In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size, Eur. J. Pharm. Sci., 27, 27, 10.1016/j.ejps.2005.08.002

Yang, 2014, Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation, Mol. Pharm., 11, 1250, 10.1021/mp400703d

Braeckmans, 2010, Sizing nanomatter in biological fluids by fluorescence single particle tracking, Nano Lett., 10, 4435, 10.1021/nl103264u

Zara, 2002, Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues, J. Drug Target., 10, 327, 10.1080/10611860290031868

Khalid, 2006, Long circulating poly(ethylene glycol)-decorated lipid nanocapsules deliver docetaxel to solid tumors, Pharm. Res., 23, 752, 10.1007/s11095-006-9662-5

Peracchia, 1999, Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting, J. Control. Release, 60, 121, 10.1016/S0168-3659(99)00063-2

DeRouchey, 2006, Decorated rods: a “bottom-up” self-assembly of monomolecular DNA complexes, J. Phys. Chem. B, 110, 4548, 10.1021/jp053760a

Vittaz, 1996, Effect of PEO surface density on long-circulating PLA-PEO nanoparticles which are very low complement activators, Biomaterials, 17, 1575, 10.1016/0142-9612(95)00322-3

Meng, 2004, Polyethylene glycol-grafted polystyrene particles, J. Biomed. Mater. Res. A, 70, 49, 10.1002/jbm.a.30056

Perry, 2012, PEGylated PRINT nanoparticles: the impact of PEG density on protein binding, macrophage association, biodistribution, and pharmacokinetics, Nano Lett., 12, 5304, 10.1021/nl302638g

Merkel, 2011, Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles, Proc. Natl. Acad. Sci. U. S. A., 108, 586, 10.1073/pnas.1010013108

van Lookeren Campagne, 2007, Macrophage complement receptors and pathogen clearance, Cell. Microbiol., 9, 2095, 10.1111/j.1462-5822.2007.00981.x

Unsworth, 2008, Protein-resistant poly(ethylene oxide)-grafted surfaces: chain density-dependent multiple mechanisms of action, Langmuir, 24, 1924, 10.1021/la702310t

Choi, 2011, Targeting kidney mesangium by nanoparticles of defined size, Proc. Natl. Acad. Sci. U. S. A., 108, 6656, 10.1073/pnas.1103573108

Vonarbourg, 2006, Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake, J. Biomed. Mater. Res. A, 78, 620, 10.1002/jbm.a.30711

Lai, 2007, Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus, Proc. Natl. Acad. Sci. U. S. A., 104, 1482, 10.1073/pnas.0608611104

Jiang, 2013, Plasmid-templated shape control of condensed DNA-block copolymer nanoparticles, Adv. Mater., 25, 227, 10.1002/adma.201202932

Champion, 2006, Role of target geometry in phagocytosis, Proc. Natl. Acad. Sci. U. S. A., 103, 4930, 10.1073/pnas.0600997103

Shi, 2002, Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions, Biochem. J., 366, 333, 10.1042/bj20020590

Anselmo, 2015, Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting, ACS Nano, 9, 3169, 10.1021/acsnano.5b00147

Dobrovolskaia, 2008, Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution, Mol. Pharm., 5, 487, 10.1021/mp800032f

Ziemba, 2012, Influence of dendrimers on red blood cells, Cell. Mol. Biol. Lett., 17, 21, 10.2478/s11658-011-0033-9

Fischer, 2003, In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis, Biomaterials, 24, 1121, 10.1016/S0142-9612(02)00445-3

Eliyahu, 2002, Lipoplex-induced hemagglutination: potential involvement in intravenous gene delivery, Gene Ther., 9, 850, 10.1038/sj.gt.3301705

Kurosaki, 2010, Chondroitin sulfate capsule system for efficient and secure gene delivery, J. Pharm. Pharm. Sci., 13, 351, 10.18433/J3GK52

Petersen, 2002, Synthesis, characterization, and biocompatibility of polyethylenimine-graft-poly(ethylene glycol) block copolymers, Macromolecules, 35, 6867, 10.1021/ma012060a

Qi, 2009, PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression, AAPS J., 11, 395, 10.1208/s12248-009-9116-1

Petersen, 2002, Polyethylenimine-graft-poly(ethylene glycol) copolymers: influence of copolymer block structure on DNA complexation and biological activities as gene delivery system, Bioconjug. Chem., 13, 845, 10.1021/bc025529v

Knop, 2010, Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives, Angew. Chem. Int. Ed. Engl., 49, 6288, 10.1002/anie.200902672

Verhoef, 2014, Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics, Drug Discov. Today, 19, 1945, 10.1016/j.drudis.2014.08.015

Abu Lila, 2013, The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage, J. Control. Release, 172, 38, 10.1016/j.jconrel.2013.07.026

Mitragotri, 2014, Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies, Nat. Rev. Drug Discov., 13, 655, 10.1038/nrd4363

Richter, 1984, Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors, Int. Arch. Allergy Appl. Immunol., 74, 36, 10.1159/000233512

Ishida, 2005, Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes, J. Control. Release, 105, 305, 10.1016/j.jconrel.2005.04.003

Ichihara, 2010, Anti-PEG IgM response against PEGylated liposomes in mice and rats, Pharmaceutics, 3, 1, 10.3390/pharmaceutics3010001

Ishida, 2006, Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes, J. Control. Release, 112, 15, 10.1016/j.jconrel.2006.01.005

Dams, 2000, Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes, J. Pharmacol. Exp. Ther., 292, 1071

Mishra, 2004, PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles, Eur. J. Cell Biol., 83, 97, 10.1078/0171-9335-00363

Shimizu, 2013, Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon, Immunobiology, 218, 725, 10.1016/j.imbio.2012.08.274

Ishida, 2006, Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes, J. Control. Release, 115, 243, 10.1016/j.jconrel.2006.08.001

Ishida, 2008, The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats, J. Control. Release, 126, 162, 10.1016/j.jconrel.2007.11.009

Ishida, 2007, PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner, J. Control. Release, 122, 349, 10.1016/j.jconrel.2007.05.015

Saadati, 2013, Accelerated blood clearance of PEGylated PLGA nanoparticles following repeated injections: effects of polymer dose, PEG coating, and encapsulated anticancer drug, Pharm. Res., 30, 985, 10.1007/s11095-012-0934-y

Tagami, 2011, Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA, J. Control. Release, 151, 149, 10.1016/j.jconrel.2010.12.013

Abu Lila, 2012, Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application, Int. J. Pharm., 438, 176, 10.1016/j.ijpharm.2012.08.030

Ishida, 2006, Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection, J. Control. Release, 115, 251, 10.1016/j.jconrel.2006.08.017

Tagami, 2010, CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes, J. Control. Release, 142, 160, 10.1016/j.jconrel.2009.10.017

Judge, 2005, Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA, Nat. Biotechnol., 23, 457, 10.1038/nbt1081

Judge, 2006, Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes, Mol. Ther., 13, 328, 10.1016/j.ymthe.2005.09.014

Tagami, 2009, Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production, J. Control. Release, 137, 234, 10.1016/j.jconrel.2009.04.006

Shimizu, 2012, Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response, Biol. Pharm. Bull., 35, 1336, 10.1248/bpb.b12-00276

Xu, 2014, Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection, Drug Deliv., 22, 598, 10.3109/10717544.2014.885998

Shiraishi, 2013, Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon, J. Control. Release, 165, 183, 10.1016/j.jconrel.2012.11.016

Wang, 2005, Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats, J. Control. Release, 104, 91, 10.1016/j.jconrel.2005.01.008

Koide, 2008, Particle size-dependent triggering of accelerated blood clearance phenomenon, Int. J. Pharm., 362, 197, 10.1016/j.ijpharm.2008.06.004

Saifer, 2014, Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins, Mol. Immunol., 57, 236, 10.1016/j.molimm.2013.07.014

Sherman, 2012, Role of the methoxy group in immune responses to mPEG-protein conjugates, Bioconjug. Chem., 23, 485, 10.1021/bc200551b

Ishihara, 2009, Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles, Pharm. Res., 26, 2270, 10.1007/s11095-009-9943-x

Armstrong, 2009, The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol), 147

Garay, 2012, Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents, Expert Opin. Drug Deliv., 9, 1319, 10.1517/17425247.2012.720969

Li, 2008, Polymer–drug conjugates: recent development in clinical oncology, Adv. Drug Deliv. Rev., 60, 886, 10.1016/j.addr.2007.11.009

Kainthan, 2007, In vivo biological evaluation of high molecular weight hyperbranched polyglycerols, Biomaterials, 28, 4779, 10.1016/j.biomaterials.2007.07.046

Amoozgar, 2012, Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley interdisciplinary reviews, Nanomed. Nanobiotechnol., 4, 219, 10.1002/wnan.1157

Abu Lila, 2013, Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration, Int. J. Pharm., 456, 235, 10.1016/j.ijpharm.2013.07.059

Abu Lila, 2014, Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery, J. Pharm. Sci., 103, 557, 10.1002/jps.23823

Kainthan, 2008, Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: biodistribution studies, Bioconjug. Chem., 19, 2231, 10.1021/bc800090v

Kierstead, 2015, The effect of polymer backbone chemistry on the induction of the accelerated blood clearance in polymer modified liposomes, J. Control. Release, 213, 1, 10.1016/j.jconrel.2015.06.023

Anselmo, 2013, Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells, ACS Nano, 7, 11129, 10.1021/nn404853z

Rodriguez, 2013, Minimal “Self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles, Science, 339, 971, 10.1126/science.1229568

Cone, 2009, Barrier properties of mucus, Adv. Drug Deliv. Rev., 61, 75, 10.1016/j.addr.2008.09.008

Ensign, 2012, Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery, Adv. Mater., 24, 3887, 10.1002/adma.201201800

Lai, 2009, Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues, Adv. Drug Deliv. Rev., 61, 158, 10.1016/j.addr.2008.11.002

Olmsted, 2001, Diffusion of macromolecules and virus-like particles in human cervical mucus, Biophys. J., 81, 1930, 10.1016/S0006-3495(01)75844-4

Suh, 2005, Real-time multiple-particle tracking: applications to drug and gene delivery, Adv. Drug Deliv. Rev., 57, 63, 10.1016/j.addr.2004.06.001

Huang, 2000, Molecular aspects of muco- and bioadhesion: tethered structures and site-specific surfaces, J. Control. Release, 65, 63, 10.1016/S0168-3659(99)00233-3

Sahlin, 1997, Enhanced hydrogel adhesion by polymer interdiffusion: use of linear poly(ethylene glycol) as an adhesion promoter, J. Biomater. Sci. Polym. Ed., 8, 421, 10.1163/156856297X00362

Serra, 2006, Design of poly(ethylene glycol)-tethered copolymers as novel mucoadhesive drug delivery systems, Eur. J. Pharm. Biopharm., 63, 11, 10.1016/j.ejpb.2005.10.011

Wang, 2008, Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier, Angew. Chem. Int. Ed., 47, 9726, 10.1002/anie.200803526

Cu, 2009, Controlled surface modification with poly(ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus, Mol. Pharm., 6, 173, 10.1021/mp8001254

Cu, 2011, In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery, J. Control. Release, 156, 258, 10.1016/j.jconrel.2011.06.036

Yang, 2011, Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus, Angew. Chem. Int. Ed., 50, 2597, 10.1002/anie.201006849

Ensign, 2012, Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003453

Yang, 2013, Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth, Adv. Healthcare Mater., 3, 1044, 10.1002/adhm.201300519

Tang, 2009, Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier, Proc. Natl. Acad. Sci. U. S. A., 106, 19268, 10.1073/pnas.0905998106

Xu, 2013, Scalable method to produce biodegradable nanoparticles that rapidly penetrate human mucus, J. Control. Release, 170, 279, 10.1016/j.jconrel.2013.05.035

Yu, 2012, Biodegradable mucus-penetrating nanoparticles composed of diblock copolymers of polyethylene glycol and poly(lactic–glycolic acid), Drug Deliv. Transl. Res., 2, 10.1007/s13346-011-0048-9

Yu, 2015, Liposome-based mucus-penetrating particles (MPP) for mucosal theranostics: demonstration of diamagnetic chemical exchange saturation transfer (diaCEST) magnetic resonance imaging (MRI), Nanomed.: Nanotechnol., Biol. Med., 11, 401, 10.1016/j.nano.2014.09.019

Xu, 2015, Impact of surface polyethylene glycol (PEG) density on biodegradable nanoparticle transport in mucus ex vivo and distribution in vivo, ACS Nano, 9, 9217, 10.1021/acsnano.5b03876

Lai, 2009, Micro- and macrorheology of mucus, Adv. Drug Deliv. Rev., 61, 86, 10.1016/j.addr.2008.09.012

Wang, 2011, Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure, PLoS One, 6, e21547, 10.1371/journal.pone.0021547

Lai, 2010, Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses, Proc. Natl. Acad. Sci. U. S. A., 107, 598, 10.1073/pnas.0911748107

Suk, 2009, The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles, Biomaterials, 30, 2591, 10.1016/j.biomaterials.2008.12.076

Forier, 2013, Transport of nanoparticles in cystic fibrosis sputum and bacterial biofilms by single-particle tracking microscopy, Nanomedicine (London), 8, 935, 10.2217/nnm.12.129

Konstan, 2004, Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution, Hum. Gene Ther., 15, 1255, 10.1089/hum.2004.15.1255

Boylan, 2012, Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation, J. Control. Release, 157, 72, 10.1016/j.jconrel.2011.08.031

Suk, 2011, N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles, Mol. Ther., 19, 1981, 10.1038/mt.2011.160

Kim, 2013, Use of single-site functionalized peg-dendrons to prepare gene vectors that penetrate human mucus barriers, Angew. Chem. Int. Ed. Engl., 52, 3985, 10.1002/anie.201208556

Suk, 2014, Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier, J. Control. Release, 178, 8, 10.1016/j.jconrel.2014.01.007

Mastorakos, 2015, Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapy, Proc. Natl. Acad. Sci. U. S. A., 112, 8720, 10.1073/pnas.1502281112

O'Riordan, 1999, PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo, Hum. Gene Ther., 10, 1349, 10.1089/10430349950018021

Yang, 2012, Immobilization of pseudorabies virus in porcine tracheal respiratory mucus revealed by single particle tracking, PLoS One, 7, 10.1371/journal.pone.0051054

Schuster, 2013, Nanoparticle diffusion in respiratory mucus from humans without lung disease, Biomaterials, 34, 3439, 10.1016/j.biomaterials.2013.01.064

Lai, 2011, Drug carrier nanoparticles that penetrate human chronic rhinosinusitis mucus, Biomaterials, 32, 6285, 10.1016/j.biomaterials.2011.05.008

Brooking, 2001, Transport of nanoparticles across the rat nasal mucosa, J. Drug Target., 9, 267, 10.3109/10611860108997935

Tobio, 1998, Stealth PLA-PEG nanoparticles as protein carriers for nasal administration, Pharm. Res., 15, 270, 10.1023/A:1011922819926

Vila, 2004, Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density, J. Control. Release, 98, 231, 10.1016/j.jconrel.2004.04.026

Tobio, 2000, The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration, Colloids Surf. B: Biointerfaces, 18, 315, 10.1016/S0927-7765(99)00157-5

Feeney, 2014, ‘Stealth’ lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug, J. Control. Release, 192, 219, 10.1016/j.jconrel.2014.07.037

Cheng, 2003, PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route, Pharm. Res., 20, 1444, 10.1023/A:1025714412337

Ensign, 2012, Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers, Adv. Drug Deliv. Rev., 64, 557, 10.1016/j.addr.2011.12.009

Yuan, 2013, Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles, Mol. Pharm., 10, 1865, 10.1021/mp300649z

Inchaurraga, 2014, In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration, Eur. J. Pharm. Biopharm.

Maisel, 2015, Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse, J. Control. Release, 197, 48, 10.1016/j.jconrel.2014.10.026

Ensign, 2013, Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues, Mol. Pharm., 10, 2176, 10.1021/mp400087y

Lautenschlager, 2013, PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease, Eur. J. Pharm. Biopharm., 85, 578, 10.1016/j.ejpb.2013.09.016

Thorne, 2006, In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space, Proc. Natl. Acad. Sci. U. S. A., 103, 5567, 10.1073/pnas.0509425103

Nance, 2012, A dense poly(ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003594

Nance, 2014, Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration, ACS Nano, 8, 10655, 10.1021/nn504210g

Mastorakos, 2015, Highly PEGylated DNA nanoparticles provide uniform and widespread gene transfer in the brain, Adv. Healthcare Mater., 4, 1023, 10.1002/adhm.201400800

Mastorakos, 2015

Jarvinen, 1995, Ocular absorption following topical delivery, Adv. Drug Deliv. Rev., 16, 3, 10.1016/0169-409X(95)00010-5

Giannavola, 2003, Influence of preparation conditions on acyclovir-loaded poly-d, l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability, Pharm. Res., 20, 584, 10.1023/A:1023290514575

Wang, 2008, Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that “slip” through the human mucus barrier, Angew. Chem. Int. Ed. Engl., 47, 9726, 10.1002/anie.200803526

Schopf, 2015, Topical ocular drug delivery to the back of the eye by mucus-penetrating particles, Transl. Vis. Sci. Technol., 4, 11, 10.1167/tvst.4.3.11

Mun, 2014, On the barrier properties of the cornea: a microscopy study of the penetration of fluorescently labeled nanoparticles, polymers, and sodium fluorescein, Mol. Pharm., 11, 3556, 10.1021/mp500332m

Sanders, 2007, Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer, J. Control. Release, 122, 226, 10.1016/j.jconrel.2007.05.004

Martens, 2013, Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy, Nanomedicine (London), 8, 1955, 10.2217/nnm.12.202

Xu, 2013, Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo, J. Control. Release, 167, 76, 10.1016/j.jconrel.2013.01.018

Weaver, 2008, Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses, Hum. Gene Ther., 19, 1369, 10.1089/hum.2008.091

van den Berg, 2010, Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity, J. Control. Release, 141, 234, 10.1016/j.jconrel.2009.09.005

Qiao, 2010, The use of PEGylated poly [2-(N, N-dimethylamino) ethyl methacrylate] as a mucosal DNA delivery vector and the activation of innate immunity and improvement of HIV-1-specific immune responses, Biomaterials, 31, 115, 10.1016/j.biomaterials.2009.09.032

Zhan, 2012, Effect of the poly(ethylene glycol) (PEG) density on the access and uptake of particles by antigen-presenting cells (APCs) after subcutaneous administration, Mol. Pharm., 9, 3442, 10.1021/mp300190g

Xie, 2014, Adenoviral vectors coated with cationic PEG derivatives for intravaginal vaccination against HIV-1, Biomaterials, 35, 7896, 10.1016/j.biomaterials.2014.05.056

Hatakeyama, 2013, The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors, Biol. Pharm. Bull., 36, 892, 10.1248/bpb.b13-00059

Romberg, 2008, Sheddable coatings for long-circulating nanoparticles, Pharm. Res., 25, 55, 10.1007/s11095-007-9348-7

Schneider, 2015, Minimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells, Biomaterials, 42, 42, 10.1016/j.biomaterials.2014.11.054

Davis, 2009, The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic, Mol. Pharm., 6, 659, 10.1021/mp900015y

Zuckerman, 2014, Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA, Proc. Natl. Acad. Sci. U. S. A., 111, 11449, 10.1073/pnas.1411393111

Hrkach, 2012, Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile, Sci. Transl. Med., 4, 10.1126/scitranslmed.3003651

Pamujula, 2012, Cellular delivery of PEGylated PLGA nanoparticles, J. Pharm. Pharmacol., 64, 61, 10.1111/j.2042-7158.2011.01376.x

Hu, 2007, Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells, J. Control. Release, 118, 7, 10.1016/j.jconrel.2006.11.028

Chen, 2008, Cell surface nucleolin serves as receptor for DNA nanoparticles composed of pegylated polylysine and DNA, Mol. Ther., 16, 333, 10.1038/sj.mt.6300365

Suh, 2007, PEGylation of nanoparticles improves their cytoplasmic transport, Int. J. Nanomedicine, 2, 735

Hatakeyama, 2011, A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma, Adv. Drug Deliv. Rev., 63, 152, 10.1016/j.addr.2010.09.001

Kolishetti, 2010, Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy, Proc. Natl. Acad. Sci. U. S. A., 107, 17939, 10.1073/pnas.1011368107

Gu, 2008, Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers, Proc. Natl. Acad. Sci. U. S. A., 105, 2586, 10.1073/pnas.0711714105

Dhar, 2011, Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo, Proc. Natl. Acad. Sci. U. S. A., 108, 1850, 10.1073/pnas.1011379108

Dhar, 2008, Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles, Proc. Natl. Acad. Sci. U. S. A., 105, 17356, 10.1073/pnas.0809154105

Karnik, 2008, Microfluidic platform for controlled synthesis of polymeric nanoparticles, Nano Lett., 8, 2906, 10.1021/nl801736q

Valencia, 2012, Microfluidic technologies for accelerating the clinical translation of nanoparticles, Nat. Nanotechnol., 7, 623, 10.1038/nnano.2012.168

Boury, 1995, Dynamic properties of poly(DL-lactide) and polyvinyl alcohol monolayers at the air/water and dichloromethane/water interfaces, J. Colloid Interface Sci., 169, 380, 10.1006/jcis.1995.1047

Zambaux, 1998, Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method, J. Control. Release, 50, 31, 10.1016/S0168-3659(97)00106-5

Sahoo, 2002, Residual polyvinyl alcohol associated with poly (d, l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake, J. Control. Release, 82, 105, 10.1016/S0168-3659(02)00127-X

Li, 2001, PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats, J. Control. Release, 71, 203, 10.1016/S0168-3659(01)00218-8

Park, 2009, PEGylated PLGA nanoparticles for the improved delivery of doxorubicin, Nanomed.: Nanotechnol., Biol. Med., 5, 410, 10.1016/j.nano.2009.02.002

Khalil, 2013, Pharmacokinetics of curcumin-loaded PLGA and PLGA–PEG blend nanoparticles after oral administration in rats, Colloids Surf. B: Biointerfaces, 101, 353, 10.1016/j.colsurfb.2012.06.024

Esmaeili, 2008, PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution, Int. J. Pharm., 349, 249, 10.1016/j.ijpharm.2007.07.038

Sheng, 2009, In vitro macrophage uptake and in vivo biodistribution of PLA–PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content, J. Mater. Sci. Mater. Med., 20, 1881, 10.1007/s10856-009-3746-9

Yang, 2014, Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol, J. Control. Release, 192, 202, 10.1016/j.jconrel.2014.07.045

Torchilin, 2003

Lee, 2007, Nanoparticles of poly(lactide)–tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery, Biomaterials, 28, 2041, 10.1016/j.biomaterials.2007.01.003

Mert, 2012, A poly(ethylene glycol)-based surfactant for formulation of drug-loaded mucus penetrating particles, J. Control. Release, 157, 455, 10.1016/j.jconrel.2011.08.032

Mi, 2011, Formulation of Docetaxel by folic acid-conjugated D-alpha-tocopheryl polyethylene glycol succinate 2000 (Vitamin E TPGS(2k)) micelles for targeted and synergistic chemotherapy, Biomaterials, 32, 4058, 10.1016/j.biomaterials.2011.02.022

Mu, 2002, Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol (R)), J. Control. Release, 80, 129, 10.1016/S0168-3659(02)00025-1

Zhang, 2006, Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release, Biomaterials, 27, 262, 10.1016/j.biomaterials.2005.05.104

Lin, 2009, Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications, Biomaterials, 30, 5114, 10.1016/j.biomaterials.2009.06.004

Chan, 2009, PLGA-lecithin-PEG core–shell nanoparticles for controlled drug delivery, Biomaterials, 30, 1627, 10.1016/j.biomaterials.2008.12.013

Wang, 2010, PLGA/polymeric liposome for targeted drug and gene co-delivery, Biomaterials, 31, 8741, 10.1016/j.biomaterials.2010.07.082

Pulkkinen, 2008, Three-step tumor targeting of paclitaxel using biotinylated PLA-PEG nanoparticles and avidin–biotin technology: formulation development and in vitro anticancer activity, Eur. J. Pharm. Biopharm., 70, 66, 10.1016/j.ejpb.2008.04.018

Kim, 2008, Systematic investigation of polyamidoamine dendrimers surface-modified with poly(ethylene glycol) for drug delivery applications: synthesis, characterization, and evaluation of cytotoxicity, Bioconjug. Chem., 19, 1660, 10.1021/bc700483s

Sweet, 2009, Transepithelial transport of PEGylated Anionic poly(amidoamine) dendrimers: implications for oral drug delivery, J. Control. Release, 138, 78, 10.1016/j.jconrel.2009.04.022

Kim, 2009, PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors, Bioconjug. Chem., 20, 1888, 10.1021/bc9001689

Perrault, 2009, Synthesis and surface modification of highly monodispersed, spherical gold nanoparticles of 50–200nm, J. Am. Chem. Soc., 131, 17042, 10.1021/ja907069u

Uster, 1996, Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time, FEBS Lett., 386, 243, 10.1016/0014-5793(96)00452-8

Nakamura, 2012, Comparative studies of polyethylene glycol-modified liposomes prepared using different PEG-modification methods, Biochim. Biophys. Acta Biomembr., 1818, 2801, 10.1016/j.bbamem.2012.06.019

Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov., 4, 145, 10.1038/nrd1632

Cavalli, 2006, The chemical modification of liposome surfaces via a copper-mediated [3+2] azide-alkyne cycloaddition monitored by a colorimetric assay, Chem. Commun., 3193, 10.1039/B606930D

Kumar, 2010, “Clickable”, polymerized liposomes as a versatile and stable platform for rapid optimization of their peripheral compositions, Chem. Commun., 46, 5746, 10.1039/c0cc00784f

Sheng, 2009, Long-circulating polymeric nanoparticles bearing a combinatorial coating of PEG and water-soluble chitosan, Biomaterials, 30, 2340, 10.1016/j.biomaterials.2008.12.070

Wuelfing, 1998, Nanometer gold clusters protected by surface-bound monolayers of thiolated poly(ethylene glycol) polymer electrolyte, J. Am. Chem. Soc., 120, 12696, 10.1021/ja983183m

Xia, 2012, Quantifying the coverage density of poly(ethylene glycol) chains on the surface of gold nanostructures, ACS Nano, 6, 512, 10.1021/nn2038516

Valencia, 2011, Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles, Biomaterials, 32, 6226, 10.1016/j.biomaterials.2011.04.078

Avgoustakis, 2003, Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles, Int. J. Pharm., 259, 115, 10.1016/S0378-5173(03)00224-2

Heald, 2002, Poly(lactic acid)-poly(ethylene oxide) (PLA-PEG) nanoparticles: NMR studies of the central solidlike PLA core and the liquid PEG corona, Langmuir, 18, 3669, 10.1021/la011393y

Garcia-Fuentes, 2004, Application of NMR spectroscopy to the characterization of PEG-stabilized lipid nanoparticles, Langmuir, 20, 8839, 10.1021/la049505j

Sun, 2010, PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo, ACS Nano, 4, 2402, 10.1021/nn100190v

Xu, 2010, Immunoaffinity purification using anti-PEG antibody followed by two-dimensional liquid chromatography/tandem mass spectrometry for the quantification of a PEGylated therapeutic peptide in human plasma, Anal. Chem., 82, 6877, 10.1021/ac1009832

Chuang, 2010, Measurement of poly(ethylene glycol) by cell-based anti-poly(ethylene glycol) ELISA, Anal. Chem., 82, 2355, 10.1021/ac902548m

Su, 2010, Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies, Bioconjug. Chem., 21, 1264, 10.1021/bc100067t

Cheng, 2005, Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles, Bioconjug. Chem., 16, 1225, 10.1021/bc050133f

Zabaleta, 2007, An HPLC with evaporative light scattering detection method for the quantification of PEGs and Gantrez in PEGylated nanoparticles, J. Pharm. Biomed. Anal., 44, 1072, 10.1016/j.jpba.2007.05.006

Nair, 2006, Comparison of electrospray ionization mass spectrometry and evaporative light scattering detections for the determination of Poloxamer 188 in itraconazole injectable formulation, J. Pharm. Biomed. Anal., 41, 725, 10.1016/j.jpba.2005.12.028

Zillies, 2007, Method for quantifying the PEGylation of gelatin nanoparticle drug carrier systems using asymmetrical flow field-flow fractionation and refractive index detection, Anal. Chem., 79, 4574, 10.1021/ac062135e